Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$0.12 - $0.3 $21,262 - $53,156
177,189 Added 5.41%
3,449,805 $413,000
Q4 2022

Feb 13, 2023

SELL
$0.09 - $0.16 $9,636 - $17,132
-107,075 Reduced 3.17%
3,272,616 $337,000
Q3 2022

Nov 14, 2022

BUY
$0.14 - $1.07 $590 - $4,513
4,218 Added 0.12%
3,379,691 $514,000
Q2 2022

Aug 12, 2022

BUY
$0.88 - $1.73 $129,983 - $255,534
147,708 Added 4.58%
3,375,473 $2.97 Million
Q1 2022

May 13, 2022

BUY
$1.14 - $2.09 $176,818 - $324,167
155,104 Added 5.05%
3,227,765 $4 Million
Q4 2021

Feb 11, 2022

SELL
$1.67 - $2.76 $9,841 - $16,264
-5,893 Reduced 0.19%
3,072,661 $5.99 Million
Q3 2021

Nov 12, 2021

BUY
$2.62 - $3.45 $171,206 - $225,443
65,346 Added 2.17%
3,078,554 $8.44 Million
Q2 2021

Aug 13, 2021

BUY
$1.96 - $3.15 $3.87 Million - $6.23 Million
1,976,385 Added 190.62%
3,013,208 $9.49 Million
Q1 2021

May 12, 2021

BUY
$1.89 - $2.96 $1.42 Million - $2.22 Million
748,784 Added 259.96%
1,036,823 $2.21 Million
Q4 2020

Feb 12, 2021

BUY
$0.65 - $1.94 $23,648 - $70,583
36,383 Added 14.46%
288,039 $558,000
Q1 2020

May 14, 2020

BUY
$0.32 - $0.8 $660 - $1,650
2,063 Added 0.83%
251,656 $110,000
Q4 2019

Feb 13, 2020

BUY
$0.3 - $1.41 $24,222 - $113,844
80,741 Added 47.82%
249,593 $172,000
Q2 2019

Aug 14, 2019

BUY
$0.54 - $1.33 $7,773 - $19,145
14,395 Added 9.32%
168,852 $122,000
Q4 2018

Feb 13, 2019

BUY
$1.28 - $2.24 $22,682 - $39,695
17,721 Added 12.96%
154,457 $231,000
Q2 2018

Aug 14, 2018

BUY
$0.85 - $1.5 $90,643 - $159,958
106,639 Added 354.32%
136,736 $187,000
Q2 2017

Aug 14, 2017

BUY
N/A
30,097
30,097 $56,000

Others Institutions Holding VTGN

About VistaGen Therapeutics, Inc.


  • Ticker VTGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 206,836,000
  • Market Cap $720M
  • Description
  • VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III d...
More about VTGN
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.